P2.09-40 Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study

Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic-based therapy in Osimertinib resistant NSCLC patients and assess the efficacy of Anlotinib in vitro study.